Rhythm Pharmaceuticals Stock
Rhythm Pharmaceuticals Stock
The price for the Rhythm Pharmaceuticals stock decreased slightly today. Compared to yesterday there is a change of -€0.500 (-0.580%).
With 39 Buy predictions and not a single Sell prediction Rhythm Pharmaceuticals is an absolute favorite of our community.
As a result the target price of 98 € shows a slightly positive potential of 14.62% compared to the current price of 85.5 € for Rhythm Pharmaceuticals.
For the coming years our community has positive and negative things to say abot the Rhythm Pharmaceuticals stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Rhythm Pharmaceuticals in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Rhythm Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals | -0.580% | -2.778% | -6.417% | 67.240% | -6.417% | 224.074% | 212.500% |
| Ardelyx Inc. | 2.410% | -7.887% | 19.572% | 19.401% | 18.404% | 129.428% | 3.304% |
| Evolus Inc | -0.930% | -9.504% | -25.763% | -56.200% | -19.633% | -54.375% | -6.809% |
| Champions Oncology Inc | - | 7.143% | 2.564% | -36.842% | 3.448% | 50.000% | -34.426% |
Comments
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Needham & Company LLC from $145.00 to $148.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at HC Wainwright from $110.00 to $123.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for RYTM provided by MarketBeat